Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments (2024 - 2025)

Historic Change in Acquisitions & Divestments for SAB Biotherapeutics (SABS) over the last 2 years, with Q2 2025 value amounting to $5.2 million.

  • SAB Biotherapeutics' Change in Acquisitions & Divestments changed N/A to $5.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year change of. This contributed to the annual value of $25.8 million for FY2024, which is N/A changed from last year.
  • Per SAB Biotherapeutics' latest filing, its Change in Acquisitions & Divestments stood at $5.2 million for Q2 2025.
  • SAB Biotherapeutics' Change in Acquisitions & Divestments' 5-year high stood at $10.7 million during Q4 2024, with a 5-year trough of $3.8 million in Q3 2024.